Aytu Biopharma (AYTU) EBT (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of EBT data on file, last reported at -$5.6 million in Q1 2026.

• On a quarterly basis, EBT fell 246.88% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$33.7 million, a 1165.17% decrease from a year earlier, with the FY2025 full-year figure at -$13.7 million, down 32.44% from the prior year.
• EBT for Q1 2026 stood at -$5.6 million, up from -$10.6 million in the prior quarter.
• Over the last five years, EBT for AYTU reached as high as $3.8 million in Q1 2025 and fell as low as -$53.3 million in Q1 2022.
• Historically, EBT has averaged -$7.3 million across 5 years, with a median of -$2.5 million in 2024.
• On a YoY basis, EBT climbed as much as 316.07% in 2025 and fell as far as 2870.68% in 2025.
• Year by year, EBT stood at -$6.7 million in 2022, then surged by 120.9% to $1.4 million in 2023, then plunged by 72.69% to $382000.0 in 2024, then plunged by 2870.68% to -$10.6 million in 2025, then jumped by 47.01% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$5.6 million in Q1 2026, -$10.6 million in Q4 2025, and $2.0 million in Q3 2025.